Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine

Internal Medicine

Volumn 48, Issue 5, 2009, Pages 265-271

  Derosa, Giuseppe ^a   Mereu, Roberto ^a   Salvadeo, Sibilla A T ^a   D'Angelo, Angela ^a   Ciccarelli, Leonardina ^b   Piccini, Mario N ^c   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Maffioli, Pamela ^a   Cicero, Arrigo F G ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b RSA Don Leone Porta   (Italy)

^c Fondazione Ospedale Della Caritá   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Intolerance; Metformin; Pioglitazone; Sibutramine; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SIBUTRAMINE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANOREXIGENIC AGENT; ANTIDIABETIC AGENT; CYCLOBUTANE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; DRUG COMBINATION; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

APPETITE DEPRESSANTS; BLOOD GLUCOSE; BLOOD PRESSURE; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; OBESITY; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 66149172390     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1670     Document Type: Article

References (41)

1. Jellinger PS, Davidson JA, Blonde L, Einhorn D, Grunberger G, Handelsman Y, Hellman R, Lebovitz H, Levy P, Roberts VL; ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract 13: 260-268, 2007.
2. American Diabetes Association. Nutrition Principles and Recommendations in Diabetes. Diabetes Care 27: 36-46, 2004.
3. American Diabetes Association. Physical Activity/Exercise and Diabetes. Diabetes Care 27: 58-62, 2004.
4. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 99 (4A): 68B-79B, 2007.
5. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399, 2007.
6. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 9: 386-393, 2007.
7. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21: 1443-1455, 2007.
8. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus: a position statement of American Diabetes Association. Diabetes Care 30: S48-S65, 2007.
9. American Diabetes Association. Screening for diabetes (Position Statement). Diabetes Care 24: S21-S24, 2001.
10. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. Geneva: WHO; June 1997.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
12. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 200: 21-27, 1978.
13. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 16: 716-730, 1999.
14. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260-266, 1972.
15. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 15: 121-130, 1978.
16. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. 2nd English ed. Bergmeyer HU, Ed. Academic Press, New York, 1974: 18-31.
17. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
19. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. McGraw-Hill, New York, 1971.
20. Bloomgarden ZT. Insulin resistance concepts. Diabetes Care 30: 1320-1326, 2007.
21. Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 4: 13-19, 2007.
22. Meneghini L, Hirsch IB. Pharmacotherapies for diabetes management: an update for the practicing clinician. Semin Thorac Cardiovasc Surg 18: 379-389, 2006.
23. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 25: 2991-3026, 2003.
24. Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, Shimada K, Kario K. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 30: 23-30, 2007.
25. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38: 865-873, 2007.
26. Schöndorf T, Forst T, Hohberg C, Pahler S, Link C, Roth W, Pfützner A, Lübben G, Link C, Pfutzner A. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab 9: 132-133, 2007.
27. Granberry MC, Hawkins JB, Franks AM. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. Am J Health Syst Pharm 64: 931-936, 2007.
28. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Al-Inter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298: 2634-2643, 2007.
29. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 26: 744-754, 2004.
30. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 37: 79-86, 2007.
31. Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 8: 197-205, 2006.
32. Kelly AS, Bank AJ. The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications 21: 326-334, 2007.
33. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 166: 1307-1308, 2002.
34. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106: 2459-2465, 2002.
35. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 26: S38-S41, 2002.
36. Derosa G, Cicero AFG, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 7: 47-55, 2005.
37. Derosa G, Cicero AFG, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 17: 222-229, 2004.
38. Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by betaadrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 16: 13-19, 2002.
39. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16: 5-11, 2002.
40. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 30: 387-394, 2007.
41. Derosa G, Cicero AF, Dangelo A, Gaddi A, Ragonesi PD, Piccinni MN, Salvadeo S, Ciccarelli L, Pricolo F, Ghelfi M, Ferrari I, Montagna L, Fogari R. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 28: 917-924, 2005.